Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine, Arsenic Trioxide and Ascorbic Acid for MDS
NCT00621023Phase 2Completed
- Sponsor
- Duke University
- Start
- Nov 2007
- Primary completion
- Apr 2010
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in myelodysplastic syndrome (MDS), sponsored by Duke University. Primary endpoint: Overall Response Rate (CR + PR). Started Nov 2007; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00621023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00621023.